Prev Chronic DisPreventing Chronic Disease1545-1151Centers for Disease Control and Prevention175729841955406PCDv43_07_0081Letter to the EditorMedical Treatment and Weight GainMcGinnEileenMPHStudent, Hunter College of the City University of New York, Brookdale Center for Healthy Aging and Longevity, New York, NY72007156200743A802007To the Editor:

"Addressing the Obesity Epidemic: A Genomics Perspective" in your April 2007 (1) issue speaks of the importance of considering all aspects of obesity. However, one aspect overlooked in the article is weight gain associated with medical treatment. Many classes of drugs are associated with weight gain that leads to overweight or obesity; these include atypical antipsychotic drugs, lithium, some antidepressant drugs, some antiepileptic drugs, and some steroids. Other drugs are associated with fat redistribution (e.g., some drugs for HIV/AIDS).

In addition to increasing weight, atypical antipsychotic drugs increase risk for hyperglycemia (as noted in a black-box label required by the Food and Drug Administration [FDA]), and they are associated with lipid dysregulation (2). Atypical antipsychotic drugs induce excitation and hypomania or mania, adverse effects never reported for the older versions of typical antipsychotic drugs (3). Some atypical antipsychotic drugs are also noncardiac QTc-interval–prolonging drugs and are associated with increased sudden cardiac death (4).

Atypical antipsychotic drugs are widely used off-label. The FDA issued a Public Health Advisory warning of a 60% to 70% increased risk for mortality among elderly people with dementia being treated with atypical antipsychotic medications (5). From 1993 through 2002, prescriptions for atypical antipsychotic drugs for American children increased 500% (all off-label); 85% of those prescriptions were for nonpsychotic conditions (6). The public health implications of wide off-label use of this class of drugs merits more study.

Read the author's reply

NewellAZlotASilveyKAriailK2007442A31Addressing the obesity epidemic: a genomics perspectivePrev Chronic DisAvailable from:http://www.cdc.gov/PCD/issues/2007/apr/06_0068.htm17362622NewcomerJW200768Suppl 12027Metabolic considerations in the use of antipsychotic medications: a review of recent evidenceJ Clin Psychiatry17286524RachidFBertschyGBondolfiGAubryJM651111200415371545Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported casesJ Clin Psychiatry15554769StrausSMSturkenboomMCBleuminkGSDielemanJPvan der LeiJde GraeffPA2619200520072012Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac deathEur Heart J158884972005Rockville (MD)Food and Drug AdministrationPublic health advisory: deaths with antipsychotics in elderly patients with behavioral disturbancesOlfsonMBlancoCLiuLMorenoCLajeG6362006679685National trends in the outpatient treatment of children and adolescents with antipsychotic drugsArch Gen Psychiatry16754841

The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.

Suggested citation for this article: McGinn E. Medical treatment and weight gain [letter to the editor]. Prev Chronic Dis [serial online] 2007 Jul [date cited]. Available from: URL: http://www.cdc.gov/pcd/issues/2007/jul/07_0081.htm